Investors / United States / TCG Crossover
TCG Crossover
Venture capital · Palo Alto, CA, United States · North America
TCG Crossover (TCGX) is an investment firm focused on innovative biotech companies, supporting both private and public companies. It invests out of closed-end funds and provides capital at any stage of a company's lifecycle.
Invests inHealthcare & Biotech
In its own wordsbiotechdrug developmentlife scienceshealthcaretherapeutics
Your fit with TCG Crossover
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsTCG Crossover lists 17 checked portfolio companies on its own site and is named in 12 funding rounds, 3 of them as lead. Its most frequent entry is Growth, 60% of the companies with a known first round. Its largest themes are Healthcare & Biotech (94%) and Media & Entertainment (6%). 81% of its companies are based in United States. It invests most often alongside RA Capital, Vivo Capital and The Column Group.
Counts come from funding rounds that name TCG Crossover, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundTCG Crossover does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 10% |
| Series B | 30% |
| Growth | 60% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 12 | 3 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 44th | 17 companies |
| Recent activity | 96th | 12 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 81th | 12% of companies confirmed by a round |
| Sector focus | 96th | 94% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 6 |
| Vivo Capital | 5 |
| The Column Group | 4 |
| ARCH Venture Partners | 3 |
| Venrock | 3 |
| Omega Funds | 2 |
| SR One | 2 |
| Sanofi Ventures | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1588%
- No longer answers00%
- Points to another company212%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 94% | 15% |
| Media & Entertainment | 6% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare TCG Crossover head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with TCG Crossover| Date | Company | Stage |
|---|---|---|
| 13 Oct 2026 | Series B | |
| 1 Oct 2026 | Series C+ Led | |
| 11 Aug 2026 | Series B Led | |
| 19 May 2026 | Series C+ | |
| 14 Apr 2026 | Series C+ | |
| 18 Feb 2026 | Series A | |
| 13 Feb 2026 | Round | |
| 22 Jan 2026 | Series C+ |
Round details for TCG Crossover
Amounts, full round histories and every co-investor in TCG Crossover's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
17 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Adarx Pharmaceuticals is developing next-generation siRNA therapeutics to treat various diseases. | Healthcare & Biotech | Portfolio page | ||
| Adcendo is developing a new generation of antibody-drug conjugates to address cancers with high unmet medical need. | Healthcare & Biotech | Apr 2026Series C+ | Page + round | |
| Arbor Biotechnologies develops novel gene editing treatments for people living with genetic disease | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Century Therapeutics develops cell therapies to treat autoimmune diseases and cancer. | Healthcare & Biotech | Jan 2026Round | Funding round | |
| Jan 2026Series C+ | Funding round | |||
| Immunic Therapeutics is a biotechnology company that develops oral therapies for neurologic and autoimmune diseases. | Healthcare & Biotech | Feb 2026Round | Funding round | |
| Korsana develops therapeutics to reduce the burden of neurodegenerative diseases | Healthcare & Biotech | Feb 2026Series A | Page + round | |
| Mentari Therapeutics is developing biologics for migraines | Healthcare & Biotech | May 2026Series C+ | Funding round | |
| Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases. | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Plexium develops small molecule compounds as potential treatments for high unmet medical needs | Healthcare & Biotech | Portfolio page | ||
| RayzeBio discovers and develops radiopharmaceuticals for patients living with cancer | Healthcare & Biotech | Portfolio page | ||
| Soufflé Therapeutics creates oligonucleotide therapies that target and enter cells causing a patient's disease. | Healthcare & Biotech | Oct 2026Series B | Funding round | |
| Synthekine develops cytokine therapeutics for the treatment of cancer and autoimmune, inflammatory, and metabolic diseases. | Healthcare & Biotech | Portfolio page | ||
| TriGemX Bio develops innovative medicines for the treatment of migraine. | Healthcare & Biotech | Oct 2026Series C+ | Funding round | |
| Vaderis Therapeutics is a biotech company that aims to bring breakthrough therapies to people with HHT and other rare vascular diseases. | Healthcare & Biotech | Aug 2026Series B | Funding round | |
Healthcare & BiotechMedia & Entertainment | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- tcgcrossover.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 8 Jan 2026
- Companies checked
- 17
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get TCG Crossover's profile as data
Pull TCG Crossover's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/tcgcrossover.com
# also
GET /v1/firms/tcgcrossover.com/portfolio
GET /v1/firms/tcgcrossover.com/coinvestors
GET /v1/firms/tcgcrossover.com/news